newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Grants of Inducement Awards

  • Crescent Biopharma's Compensation Committee approved equity inducement awards on April 23, 2026.
  • The awards consist of options to purchase 12,525 aggregate ordinary shares granted to two non-executive employees.
  • The grants were made under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan to facilitate employment acceptance per Nasdaq Listing Rule 5635(c)(4).
  • Each option has a 10-year term with an exercise price of $25.70, based on the April 23, 2026 closing share price.
  • Vesting terms include one-fourth of shares exercisable on the first anniversary of the start date, followed by one-fortieth-eighth monthly thereafter, contingent on continuous service.
  • Crescent Biopharma is a clinical-stage oncology company with a pipeline featuring a PD-1 x VEGF bispecific antibody \& novel antibody-drug conjugates.